Progress in the application of tumor necrosis factor ɑ inhibitors in Behcet′s disease uveitis

doi:10.3877/cma.j.issn.2095-2007.2022.01.008

Abstract

Abstract:

Behcet′s disease (BD) is a chronic autoimmune inflammatory disease. When BD has been involved in the eye, BD could cause serious complications. Behcet uveitis (BU) is characterized by recurrent episodes and regression of non-granulomatous inflammation, which has poor prognosis and a high rate of blindness. The traditional treatment for BU is to use hormone combined immunosuppressant. However, systemic adverse reactions and potential infections could occur for severe and long-term treatment patients, resulting in irreversible vision loss. In recent years, it has been demonstrated that the use of tumor necrosis factor (TNF) inhibitors could be helpful to significantly control the recurrence rate and complications of BU. The research status of TNF-ɑ inhibitors in the treatment of BU is reviewed, which could provide a new strategy for refractory BU.

Key words: Behcet′s disease uveitis, Tumor necrosis factor ɑinhibitors, Treatment, Progress

Huiyu Jia, Hong Lu. Progress in the application of tumor necrosis factor ɑ inhibitors in Behcet′s disease uveitis[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(01): 42-46.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2022.01.008

https://zhykyxzz.cma-cmc.com.cn/EN/Y2022/V12/I01/42

References 54

[1]	Salmaninejad A, Zamani MR, Shabgah AG, et al. Behçet's disease: An immunogenetic perspective[J]. Cell Physiol, 2019, 234(6): 8055-8074.
[2]	Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet's Disease: Epidemiology, Clinical Manifestations, and Diagnosis[J]. Expert Rev Clin Immunol, 2017, 13(1): 57-65.
[3]	Diedrichs MM, Kaufmann U, Wildner G. The immunopathogenesis of chronic and relapsing autoimmune uveitis Lessons from experimental rat[J]. Prog Retin Eye Res, 2018 , 65：107-126.
[4]	O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity[J]. Nat Rev Immunol.2002, 2(1): 37-45.
[5]	Kenji N, Kazuichi M, Kazuko U, et al. Simultaneous Analysis of Multiple Cytokines in the Vitreous of Patients with Sarcoid Uveitis[J]. Investigative Opthalmology & Visual Science, 2012, 53(7): 3827-3833.
[6]	Khera TK, Dick AD, Nicholson LB. Mechanisms of TNFα regulation in uveitis: focus on RNA-binding proteins[J]. Prog Retin Eye Res, 2010, 29(6): 610-621.
[7]	Nourshargh S, Alon R. Leukocyte migration into inflamed tissues[J]. Immunity.2014, 41(5): 694-707.
[8]	Bharadwaj AS, Schewitz-Bowers LP, Wei L, et al. Intercellular adhesion molecule 1 mediates migration of Th1 and Th17 cells across human retinal vascular endothelium[J]. Invest Ophthalmol Vis Sci, 2013, 54(10): 6917-6925.
[9]	Ashander LM, Binoy A, Ma Y, et al. Targeting Endothelial Adhesion Molecule Transcription for Treatment of Inflammatory Disease: A Proof-of-Concept Study[J]. Mediators of Inflammation, 2016: 1-8.
[10]	Saishin Y, Saishin Y, Takahashi K, et al. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier[J]. Journal of Cellular Physiology, 2003, 195(2): 210-219.
[11]	Nishikiori N, Osanai M, Chiba H, et al. Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy[J]. Diabetes, 2007, 56(5): 1333-1340.
[12]	Luna JD, Chan CC, Derevjanik NL, et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown[J]. Neurosci Res, 1997, 49(3): 268-280.
[13]	Aveleira Célia A, Lin CM, Abcouwer Steven F, et al. TNF-α signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability[J]. Diabetes, 2010, 59: 2872-2882.
[14]	Caspi RR. A look at autoimmunity and inflammation in the eye[J]. Clin Invest, 2010, 120(9): 3073-3083.
[15]	Nadkarni, Mauri S, Ehrenstein C, et al. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta[J]. Journal of Experimental Medicine, 2007, 204(1): 33.
[16]	Yang P, Ji L, Zhou H, et al. Disturbed expression of Fas/FasL on CD4(+) and CD8(+)T cells in Behcet's disease, Vogt-Koyanagi-Harada syndrome, and idiopathic anterior uveitis[J]. Ocul Immunol Inflamm, 2001, 9(3): 185-191.
[17]	Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel[J]. Am J Ophthalmol, 2000, 130(4): 492-513.
[18]	Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial[J]. Lancet, 2009, 374 (9685): 210-221.
[19]	Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients[J]. Autoimmun, 2015, 62: 67-74.
[20]	Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis[J]. Expert Opin Biol Ther, 2019, 19(5): 477-490.
[21]	Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis[J]. Arthritis Care Res (Hoboken), 2019, 71(6): 703-716.
[22]	Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients[J]. Clin Rheumatol, 2019, 38(2): 407-415.
[23]	Santos-Gómez M, Calvo-Río V, Blanco R, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study[J]. Clin Exp Rheumatol, 2016, 34(6): 34-40.
[24]	Hu Y, Huang Z, Yang S, et al. Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets' Disease-Associated Uveitis: A Systematic Review and Meta-Analysis[J]. Front Pharmacol, 2020, 11: 941.
[25]	Lamattina KC, Goldstein DA. Adalimumab for the treatment of uveitis[J]. Expert Rev Clin Immunol, 2017, 13(3): 181.
[26]	Diaz-Llopis M, García-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study[J]. Ocul Pharmacol Ther, 2008, 24(3): 351-361.
[27]	La TF, Cattalini M, Teruzzi B, et al. Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series s[J]. BMC Research Notes, 2014, 7(1): 316.
[28]	Mccracken C, Yeh S, Jenkins K, et al. Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis[J]. Eye, 2019, 33(4): 629-639.
[29]	Halilbasic M, Vodencarevic AN, Cosickic A, et al. Adalimumab in Treatment of Uveitis in Pediatric Behcet's Disease-a Case Report[J]. Mater Sociomed, 2021, 33(1): 78-81.
[30]	Bawazeer A, Raffa LH. Clinical experience with adalimumab in the treatment of ocular Behet disease[J]. Ocular Immunology & Inflammation, 2010, 18(3): 226-232.
[31]	Fatima J, Amanda S. A rare case of suicidal ideation related to Adalimumab use[J]. Open Access Rheumatol, 2018, 17, (10): 113-115.
[32]	Mendes D, Alves C, Bate MF. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events[J]. Clinical Pharmacy & Therapeutics, 2014, 39(3): 307-313.
[33]	Jaffe GJ, Dick AD, Brézin A, et al. Adalimumab in Patients with Active Noninfectious Uveitis[J]. New England Journal of Medicine, 2016, 375(10): 932-943.
[34]	Fabiani C, Vitale A, Rigante D, et al. Predictors of sustained clinical response in patients with Behet's disease-related uveitis treated with infliximab and adalimumab[J]. Clinical Rheumatology, 2018, 37(6): 1715-1720.
[35]	白琳，杨培增. 白塞病葡萄膜炎的治疗与展望[J]. 中华实验眼科杂志，2016，34(8)：761-764.
[36]	Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease[J]. Lancet, 2001, 358(9278): 295-296.
[37]	孙妍，任立敏. IFX治疗难治性贝赫切特综合征眼炎1例并文献复习[J]. 中华临床免疫和变态反应杂志，2021，6(4)：4.
[38]	袁艺，史婧，刘金晶，等. 英夫利西单抗治疗难治性白塞病葡萄膜炎的疗效及安全性[J]. 中华临床免疫和变态反应杂志，2019，13(1)：62-67.
[39]	Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, et al. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients[J]. J Rheumatol, 2021, 48(5): 741-750.
[40]	Posarelli C, Arapi I, Figus M, et al. Biologic agents in inflammatory eye disease[J]. Journal of Ophthalmic & Vision Research, 2011, 6(4): 309-316.
[41]	Refaat M, Abdullatif AM, Hamza MM, et al. Monthly intravitreal infliximab in behçet's disease active posterior uveitis: A Long-Term Safety Study[J]. Retina, 2021, 41(8): 1739-1747.
[42]	张美芬，赵潺，温鑫，等. 依那西普治疗复发性白塞病葡萄膜炎的短期疗效和安全性研究[J]. 中华眼科杂志，2010，46(2)：6.
[43]	Calvo-Río V, Blanco R, Santos-Gómez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients[J]. Semin Arthritis Rheum, 2016, 46(1): 95-101.
[44]	Fabiani C, Sota J, Rigante D, et al. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet[J]. Ocul Immunol Inflamm, 2019, 27(1): 58-63.
[45]	Palmou-Fontana N, Calvo-Río V, Martín-Varillas JL, et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review[J]. Clin Exp Rheumatol, 2018, 36(4): 652-657.
[46]	Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome[J]. Annals of the Rheumatic Diseases, 2018, 77(6): 808-818.
[47]	Hwang DK, Hwang YS, Tsai ML, et al. Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan[J]. Taiwan J Ophthalmol, 2018, 8(3): 117-120.
[48]	Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Fundamentals of Care for Uveitis International Consensus Group. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative[J]. Ophthalmology, 2018, 125(5): 757-773.
[49]	Keino H, Okada AA, Watanabe T, et al. Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study[J]. Ocular Immunology & Inflammation, 2016, 25(1): 46-51.
[50]	Hiyama T, Harada Y, Doi T, et al. Early administration of adalimumab for paediatric uveitis due to Behçet's disease[J]. Pediatric Rheumatology, 2019，17(1) : 29.
[51]	Hamam RN, Barikian AW, Antonios RS, et al.Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study[J]. Ocul Immunol Inflamm, 2016, 24(3): 319-326.
[52]	Kunimi K, Usui Y, Asakage M, et al. Anti-TNF-α Therapy for Refractory Uveitis Associated with Behçet's Syndrome and Sarcoidosis: A Single Center Study of 131 Patients[J]. Ocul Immunol Inflamm, 2020: 1-8.
[53]	Fabiani C, Sota J, Rigante D, et al. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies[J]. Clin Rheumatol, 2018, 37(10): 2805-2809.
[54]	Ohno S, Umebayashi I, Matsukawa M, et al. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan[J]. Arthritis Res Ther, 2019, 21(1): 2.

Please choose a citation manager

Content to export